Q3 2020: The 2020 Deal Awards & Coping with Covid
The Q3 Dealmaker Quarterly features the The Deal’s Large Cap and Middle Market Awards for 2020 and weighs the impact of Covid-19 on the dealmaking world.
The Dealmaker Quarterly
The Dealmaker Quarterly focuses on current analysis with top editors offering unique perspective and insight into the market-moving trends, ground-breaking transactions, winning tactics and strategies and the movers and shakers behind them.
Q1 2020: New World, New Rules
The Q1 Dealmaker Quarterly offers readers a deep dive into what the November U.S. presidential election could mean for antitrust, corporate governance, shareholder activism and private equity. The Quarterly also includes profiles of the latest crop of M&A partners at law firms, whom we christen Rising Stars.
Q4 2019: Diversity in Dealmaking
Our Q4 The Dealmaker Quarterly delineates the lack of gender diversity in private equity and profiles the women out to change that. Q4 also features an analysis of how middle-market PE firms are widening the scope of their dealmaking.
Q3 2019: Corporate Governance and The Activism League Tables
Our Q3 The Dealmaker Quarterly delves into the theme of disruption by examining how unicorn IPOs, cannabis and new media are changing industries ranging from finance and advertising to pharmaceuticals. Also featured are an analysis of the latest trends and a Who’s Who in corporate activism.
Q2 2019: Private Equity and The Middle Market Outlook
Our annual awards for the top deals and dealmakers of 2019 are featured in our Q2 The Dealmaker Quarterly along with a scorecard of top PE advisers and an in-depth analysis of how the middle-market landscape for dealmaking is changing.
The Dealmaker Quarterly reaches 350,000+ Corporate Dealmakers and their Advisers
For more information, including how to reach the full subscriber base
of The Deal, please contact Jenney.Smith@TheDeal.com
News From The Deal
Drinks With The Deal: Goodwin Procter's Stuart Cable
The vice chair and head of M&A discusses building the firm's biotech practice, helping Covid-19 vaccine developer Moderna grow over the years and recent transformational deals in the latest episode of the podcast.
Activist Investing Today: Goodwin on Governance, Pay as 'Wedge Issues'
Poor governance and issues with executive compensation aren't enough to warrant credible activist involvement on their own, but they can serve as a lever for shareholders that have broader outcomes in mind, says Shane Goodwin, the chief of the Applied Corporate Governance Institute.
